A group of experts will discuss today the last evidence about the polypill benefits
Beirut, January 30th – Cardiovascular diseases are the main cause of death worldwide and they are responsible for half of all deaths in Lebanon. Thus, controlling cardiovascular risk factors is essential for patients. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level.
Today’s Trinomia launch in Beirut will bring together world-class cardiologists, internists, and primary care doctors to discuss strategies for prevention of cardiovascular disease. The motive of the event is to generate awareness that will keep medical professionals abreast of the problems affecting the prevention and treatment of cardiovascular disease, and mainly focus in the incorporation of “polypill” use into clinical practice.
“The polypill comprises a combination of low-dose aspirin, a statin and an antihypertensive, and should be considered as an integral part of a comprehensive cardiovascular prevention strategy. In fact, patients with a history of myocardial infarction or stroke are recommended to take these 3 preventive medications. The pills used separately are already a standard treatment given to any patient with myocardial infarction” said Prof. Pablo Perez from Spain. He is specialist in Internal Medicine at the Reina Sofía Hospital in Córdoba and member of the Spanish Society of Arteriosclerosis.
He also explained about the benefits of this polypill “interestingly this new drug has been shown to improve adherence, better control of risk factors such as systolic blood pressure and the bad cholesterol, LDL-C, compared with usual care among patients with cardiovascular disease or at high risk of their first event”, and consequently “better medication adherence may be associated with a reduction in major cardiovascular events and cost savings”.